Holen Sie sich die Stockscreener-App
14.39
2.64%
0.37
Schlusskurs vom Vortag:
$14.02
Offen:
$14.19
24-Stunden-Volumen:
339.00K
Relative Volume:
0.79
Marktkapitalisierung:
$991.15M
Einnahmen:
$62.71M
Nettoeinkommen (Verlust:
$-112.51M
KGV:
-9.5298
EPS:
-1.51
Netto-Cashflow:
$-96.01M
1W Leistung:
-4.13%
1M Leistung:
+0.70%
6M Leistung:
+29.64%
1J Leistung:
+22.57%
1-Tages-Spanne:
$13.85
$14.40
1-Wochen-Bereich:
$13.85
$15.25
52-Wochen-Spanne:
$7.97
$17.70
Zymeworks Inc. Stock (ZYME) Company Profile
Firmenname
Zymeworks Inc.
Sektor
Branche
Telefon
604-678-1388
Adresse
1385 West 8th Avenue, Suite 540, Vancouver, BC
Vergleichen Sie ZYME mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
14.39 | 991.15M | 62.71M | -112.51M | -96.01M | -1.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-16 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-11-07 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-01 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-03-21 | Fortgesetzt | Wells Fargo | Overweight |
| 2023-01-04 | Bestätigt | H.C. Wainwright | Neutral |
| 2022-12-20 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-01 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-10-21 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-10-04 | Fortgesetzt | Wells Fargo | Overweight |
| 2022-05-05 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-03-15 | Eingeleitet | Evercore ISI | Outperform |
| 2021-12-10 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-17 | Fortgesetzt | Guggenheim | Neutral |
| 2021-10-07 | Eingeleitet | Jefferies | Hold |
| 2021-03-31 | Eingeleitet | Credit Suisse | Outperform |
| 2021-02-25 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-08 | Fortgesetzt | H.C. Wainwright | Buy |
| 2021-01-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-08-06 | Eingeleitet | SVB Leerink | Outperform |
| 2020-01-10 | Eingeleitet | Wolfe Research | Outperform |
| 2019-12-09 | Eingeleitet | JP Morgan | Neutral |
| 2019-11-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-20 | Eingeleitet | Guggenheim | Buy |
| 2019-09-30 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2019-08-30 | Eingeleitet | Stifel | Buy |
| 2019-07-18 | Eingeleitet | Deutsche Bank | Buy |
| 2018-05-11 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2018-03-19 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Zymeworks Inc. Aktie (ZYME) Neueste Nachrichten
Zymeworks Inc. (NYSE:ZYME) Receives $19.17 Average Price Target from Brokerages - MarketBeat
Brokerages Set Zymeworks Inc. (NYSE:ZYME) Target Price at $19.17 - Defense World
Zymeworks Inc. Announces Appointment of Oleg Nodelman to the Board of Directors - Marketscreener.com
Zymeworks Welcomes Oleg Nodelman to Board of Directors - TipRanks
Zymeworks Announces Appointment Of Oleg Nodelman To Board Of Directors -February 18, 2025 at 06:18 am EST - Marketscreener.com
Zymeworks Inc. Appoints Oleg Nodelman to Board of Directors as Part of Ongoing Board Renewal Process - Nasdaq
Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors - GlobeNewswire
Major Strategic Move: Zymeworks Adds Largest Shareholder's Founder to Board, Signaling Growth Focus - StockTitan
Zymeworks BC Inc (ZYME) can make a big difference with a little luck - SETE News
Zymeworks (NYSE:ZYME) Stock Price Down 5.4%Should You Sell? - MarketBeat
Q1 Earnings Forecast for Zymeworks Issued By Leerink Partnrs - MarketBeat
Zymeworks to Announce 2024 Financial Results and Host Corporate Update - TipRanks
Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025 - The Korea Bizwire
Zymeworks Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 5, 2025 - Nasdaq
Earnings Alert: Zymeworks Schedules Critical Year-End ResultsKey Details Inside - StockTitan
Zymeworks (NYSE:ZYME) Trading Down 5.4% – What’s Next? - Defense World
Zymeworks: Its Post-Approval Future (NASDAQ:ZYME) - Seeking Alpha
Recent Insider Activity Could Benefit Zymeworks BC Inc (ZYME) - Knox Daily
You might want to take a look at Zymeworks BC Inc (ZYME) now - SETE News
SG Americas Securities LLC Has $392,000 Position in Zymeworks Inc. (NYSE:ZYME) - Defense World
Zymeworks to Engage Investors at Key Conferences - TipRanks
Zymeworks Announces Participation in Upcoming Investor Conferences - The Manila Times
Cancer Drug Developer Zymeworks Takes Center Stage at Oppenheimer, Citi, and B. Riley Events - StockTitan
Zymeworks (NASDAQ:ZYME) shareholder returns have been respectable, earning 79% in 3 years - Simply Wall St
The past five years for Zymeworks (NASDAQ:ZYME) investors has not been profitable - Yahoo Finance
Zymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc Buys 19,748 Shares - MarketBeat
Zymeworks Inc. (NYSE:ZYME) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Analysts Set Zymeworks Inc. (NYSE:ZYME) PT at $19.17 - MarketBeat
EcoR1 Capital, LLC Expands Stake in Zymeworks Inc with Strategic Acquisition - GuruFocus.com
Assenagon Asset Management S.A. Raises Position in Zymeworks Inc. (NYSE:ZYME) - Defense World
Assenagon Asset Management S.A. Boosts Stake in Zymeworks Inc. (NYSE:ZYME) - MarketBeat
Engineered Multispecific Antibodies Innovation Research Report 2024: Patent Trends Show a Noticeable Surge in 2023 with Regeneron, Roche, and Amgen Emerging as the Top Patent Filers - GlobeNewswire Inc.
Zymeworks (NYSE:ZYME) Shares Gap Up Following Insider Buying Activity - Defense World
Opinion: Four trends to watch in B.C.'s tech sector - Business in Vancouver
Zymeworks (NYSE:ZYME) Shares Gap Up on Insider Buying Activity - MarketBeat
EcoR1 Capital, LLC Increases Stake in Zymeworks Inc - GuruFocus.com
ZYME (Zymeworks) Total Stockholders Equity : $366.98 Mil (As of Sep. 2024) - GuruFocus.com
Insider Buying: Zymeworks Inc. (NYSE:ZYME) Director Acquires 74,125 Shares of Stock - MarketBeat
Ecor1 capital acquires $2.28 million in Zymeworks stock By Investing.com - Investing.com Nigeria
Ecor1 Capital, Llc Buys 39,029 Shares of Zymeworks Inc. (NYSE:ZYME) Stock - MarketBeat
Ecor1 capital acquires $2.28 million in Zymeworks stock - Investing.com
Zymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc Acquires 204,098 Shares of Stock - MarketBeat
Ecor1 Capital, Llc Purchases 21,021 Shares of Zymeworks Inc. (NYSE:ZYME) Stock - MarketBeat
Ecor1 capital increases stake in Zymeworks with $2.97 million purchase By Investing.com - Investing.com South Africa
Finanzdaten der Zymeworks Inc.-Aktie (ZYME)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):